TBPH | Ticker Profile - Titan Protect

TBPH

Theravance Biopharma, Inc.

Healthcare · Biotechnology · NGM

$16.29

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$838M

Total market value of the company

Trailing P/E

7.29

Very cheap relative to earnings

Forward P/E

12.96

Based on estimated future earnings — lower means cheaper

Rev Growth

+15.0%

Year-over-year revenue change

Profit Margin

104.3%

How much profit the company keeps from each dollar of revenue

ROE

50.2%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$17.00

+4% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 5 analysts covering this stock

About Theravance Biopharma, Inc.

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

https://www.theravance.com

Country: United States Employees: 90 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.954

Good returns relative to risk taken

Kelly Fraction

0.0723

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.160

Returns exceed worst-case losses — strong risk profile

Annual Return

40.1%

Historical annualised return based on price data

Max Drawdown

-34.6%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.19

Very low correlation to market moves

52W High

$21.03

23% below the year high

52W Low

$9.10

79% above the year low

Avg Volume

581,686

Average daily shares traded — higher means easier to buy and sell

Short Ratio

14.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

15.5%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$2.23

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

13.94

Heavy leverage — higher financial risk if revenues decline

Current Ratio

13.14

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

12.91

Like current ratio but excludes inventory — stricter test

Gross Margin

71.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-33.1%

Profit from core operations before interest and tax

Free Cash Flow

$23M

Positive — the business generates more cash than it spends

Revenue (TTM)

$110M

Total revenue over the last 12 months

Net Income

$115M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$21.00

Target Median

$17.00

Target Low

$15.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go